Loading
Proved that adding a LAG-3 blocker to PD-1 blockade delays progression, with far less toxicity than the ipilimumab combination.
PFS 10.1 vs 4.6 months (HR 0.75) led to FDA approval of Opdualag in March 2022. OS was not formally significant at first analysis; extended follow-up reported median OS 51.0 vs 34.1 months with 3-year OS 54.6% vs 48.0% (JCO 2024) and a 4-year update (EJC 2025) with the upper confidence bound below 1. Grade 3-4 treatment-related events ~21% versus ~59% for nivolumab-ipilimumab in CheckMate 067.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
714 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Nivolumab + relatlimab | - | 10.1 months | 0.75 | - | link |
| Nivolumab | - | 4.6 months | ||||
| Overall survival (3-year) | Nivolumab + relatlimab | - | 54.6% | - | - | link |
| Nivolumab | - | 48% |
For patients with advanced melanoma, immunotherapy offers a realistic chance of long-term survival and probably cure, and the ten-year data show that patients who are alive and progression-free at three years rarely die of melanoma afterwards. Nivolumab plus ipilimumab gives the best long-term results but at a high price in serious side effects; nivolumab alone or nivolumab plus relatlimab are alternatives for patients at lower risk or with autoimmune concerns. The trial is also a caution about surrogate endpoints: the survival plateau took years to become visible.
A second publication from the RELATIVITY-047 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Patients with newly diagnosed advanced melanoma have a dual-checkpoint option that improves on nivolumab alone with only a modest increase in serious side effects, making it attractive for those unable to tolerate or unwilling to risk the toxicity of ipilimumab. It did not prove superior survival, and it has not been compared with nivolumab plus ipilimumab, which remains preferred for patients with brain metastases or other high-risk features. LAG-3 is now an established target under study in many other cancers.
Shares Caution: LAG-3 blockade outside active disease, Hussein A. Tawbi, Relatlimab + nivolumab, LAG-3.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Nivolumab.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Nivolumab.
Shares Relatlimab + nivolumab, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares CheckMate 067, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, PD-1.
Shares Relatlimab + nivolumab, CheckMate 067, LAG-3, Nivolumab.
Shares Relatlimab + nivolumab, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Nivolumab.